Cross-reactive neutralizing antibody against pandemic 2009 H1N1 influenza a virus in intravenous immunoglobulin preparations.
Prepandemic intravenous immunoglobulin (IVIG) and sera from Kawasaki disease patients treated with this IVIG were analyzed for 2009 H1N1-specific microneutralization and hemagglutination inhibition antibodies. All 6 different IVIG preparations tested had significant levels of cross-reactive-specific antibody at a concentration of 2.0 g/dL of immunoglobulin. Sera from 18 of 19 Kawasaki disease patients had significant increases of cross-reactive-specific antibody after 2.0 g/kg of prepandemic IVIG. These results suggest a role for adjunctive IVIG therapy for severe and/or drug-resistant 2009 H1N1 virus and other highly antigenically drifted influenza strains, particularly in the immunocompromised.
Hong
David K
DK
Division of Infectious Diseases, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
Tremoulet
Adriana H
AH
Burns
Jane C
JC
Lewis
David B
DB
D000818:Animals; D057134:Antibodies, Neutralizing / Q000008:administration & dosage / Q000276:immunology*; D002460:Cell Line; D002648:Child; D002675:Child, Preschool; D003429:Cross Reactions / Q000276:immunology; D004285:Dogs; D004306:Dose-Response Relationship, Immunologic; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000276:immunology*; D007223:Infant; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D007251:Influenza, Human / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control / Q000821:virology*; D009080:Mucocutaneous Lymph Node Syndrome / Q000276:immunology; D009500:Neutralization Tests; D058873:Pandemics
D057134:Antibodies, Neutralizing; D016756:Immunoglobulins, Intravenous